investor pres announcement. , page-14

Fair point Cgt it does seem to skip receipt of final results which I would have thought a relevant milestone. Seemed a bit dismissive anyway but wether that's born out of confidence or not we will shortly find out no doubt.
This from the 1102 main finding ann.

"Pending receipt and final data evaluation from the current study, as well as review of all the preclinical and clinical data obtained, ANP is planning future regulatory agency discussions regarding further development of ATL1102 and the dosing regimen for a future Phase IIb trial in MS patients. The Company anticipates final review of the data by June this-year and follow-up discussions with the US Food and Drug Administration (FDA) at a pre-IND meeting during the 3rd quarter 2014."

You know what really raised my eyebrow was the fact there was no specifics re this latest roadshow Melb Syd Bris.
As they say in real estate its very hard to sell a secret unless, they wanted to channel enquiries through the office...buggered if I know.